PDA

View Full Version : New Data Shows Epratuzumab Provided Significant Efficacy For Patients With Moderate T



RSS Bot
06-17-2010, 09:14 AM
UCB (EURONEXT: UCB) and Immunomedics Inc. (NASDAQ:IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE)...

More... (http://mnt.to/f/3DZy)